Xeroderma pigmentosum variant: response to etretinate.
We report a case of the variant form of xeroderma pigmentosum in whom tumour development was completely suppressed for 22 months by etretinate 25 mg daily.
Berth-Jones
J
J
Department of Dermatology, Leicester Royal Infirmary, U.K.
Graham-Brown
R A
RA
D004260:DNA Repair / Q000502:physiology; D005050:Etretinate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics; D014983:Xeroderma Pigmentosum / Q000188:drug therapy* / Q000235:genetics
D005050:Etretinate